Wed, Oct 22, 2014, 2:21 AM EDT - U.S. Markets open in 7 hrs 9 mins


% | $
Quotes you view appear here for quick access.

AcelRx Pharmaceuticals, Inc. (ACRX) Message Board

  • chimakot chimakot Sep 20, 2013 8:26 AM Flag

    Scott makes a compelling case for a buyout in his SA article today.

    Very well written, and excellent analysis on Scott's part. IMO, Scott is one of the best analysts in this sector. Let's Ride!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 3M shares short....20% of the float...shorts could wake up to a nightmare. LOL

      Sentiment: Strong Buy

    • So he says that the nda will be out by the end of septembe and there is a buyout rumor.

      the nda is not news. The buyout rumor is bs.

      the buyout rumor is the chief tool of the manipulator and bs artists -- in my 30 years it never happened. I have been bought out before but the rumor never serfaced before the buyout. Inside info gets you sent to jail.

    • Scott heard strong buyout rumors about TSRX and within days/weeks it happened. IMO, Scott is clearly connected. Let's Ride!

      We feel that AcelRx Pharmaceuticals (ACRX) warrants a close look by both longer-term investors and shorter-term catalyst traders. The major difference between Halozyme and AcelRx is that we have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. We believe there is merit to the current rumors surrounding AcelRx, and will detail the reasons why further down in this article.

      Sentiment: Strong Buy

6.85-0.05(-0.72%)Oct 21 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.